Close
Nordic 9Nordic 9

Ren Life Sciences (investor - Private Equity)

United Kingdom
See something wrong or missing? Let us know
Offices:London

Ren Life Sciences is a British PE fund launched James Mitchell and Julian Woollard to invest in European life sciences

Average round investment:N/A USD
Average number per year:0.0
Distribution: 2026 (1)
Portfolio companies: Spain 53Biologics
Mostly invests in: Spain Spain (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Ren Life Sciences

Name Criteria
Spain FC Barcelona
70%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Spain
  • Active last 12 months: Yes
Switzerland SNGLR Capital
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Active last 12 months: Yes
Austria Biogena Group Invest Ag
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Active last 12 months: Yes
Sweden Triathlon Group
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Active last 12 months: Yes
Sweden Ekeblad Bostad
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Active last 12 months: Yes
Belgium Annemie Van de Casteele
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Active last 12 months: Yes
Belgium Griet Nuytinck
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Active last 12 months: Yes
Belgium Virginie Saverys
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Active last 12 months: Yes
Italy Golgi NueroSciences
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Active last 12 months: Yes
United States Signet Healthcare Partners
67%
  • Range for average deal size: n/a USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Active last 12 months: Yes
Top